Find information on thousands of medical conditions and prescription drugs.

Systemic mastocytosis

Mastocytosis is a group of rare disorders of both children and adults caused by the presence of too many mast cells (mastocytes) in a person's body. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Sabinas brittle hair...
Saccharopinuria
Sacral agenesis
Saethre-Chotzen syndrome
Salla disease
Salmonellosis
Sandhoff disease
Sanfilippo syndrome
Sarcoidosis
Say Meyer syndrome
Scabies
Scabiophobia
Scarlet fever
Schamberg disease...
Schistosomiasis
Schizencephaly
Schizophrenia
Schmitt Gillenwater Kelly...
Sciatica
Scimitar syndrome
Sciophobia
Scleroderma
Scrapie
Scurvy
Selachophobia
Selective mutism
Seminoma
Sensorineural hearing loss
Seplophobia
Sepsis
Septo-optic dysplasia
Serum sickness
Severe acute respiratory...
Severe combined...
Sezary syndrome
Sheehan syndrome
Shigellosis
Shingles
Shock
Short bowel syndrome
Short QT syndrome
Shprintzen syndrome
Shulman-Upshaw syndrome
Shwachman syndrome
Shwachman-Diamond syndrome
Shy-Drager syndrome
Sialidosis
Sickle-cell disease
Sickle-cell disease
Sickle-cell disease
Siderosis
Silicosis
Silver-Russell dwarfism
Sipple syndrome
Sirenomelia
Sjogren's syndrome
Sly syndrome
Smallpox
Smith-Magenis Syndrome
Sociophobia
Soft tissue sarcoma
Somniphobia
Sotos syndrome
Spasmodic dysphonia
Spasmodic torticollis
Spherocytosis
Sphingolipidosis
Spinal cord injury
Spinal muscular atrophy
Spinal shock
Spinal stenosis
Spinocerebellar ataxia
Splenic-flexure syndrome
Splenomegaly
Spondylitis
Spondyloepiphyseal...
Spondylometaphyseal...
Sporotrichosis
Squamous cell carcinoma
St. Anthony's fire
Stein-Leventhal syndrome
Stevens-Johnson syndrome
Stickler syndrome
Stiff man syndrome
Still's disease
Stomach cancer
Stomatitis
Strabismus
Strep throat
Strongyloidiasis
Strumpell-lorrain disease
Sturge-Weber syndrome
Subacute sclerosing...
Sudden infant death syndrome
Sugarman syndrome
Sweet syndrome
Swimmer's ear
Swyer syndrome
Sydenham's chorea
Syncope
Syndactyly
Syndrome X
Synovial osteochondromatosis
Synovial sarcoma
Synovitis
Syphilis
Syringomas
Syringomyelia
Systemic carnitine...
Systemic lupus erythematosus
Systemic mastocytosis
Systemic sclerosis
T
U
V
W
X
Y
Z
Medicines

Pathophysiology

Mast cells are located in connective tissue, including the skin, the linings of the stomach and intestine, and other sites. They may play an important role in helping defend these tissues from disease. By releasing chemical "alarms" such as histamine, mast cells attract other key players of the immune defense system to areas of the body where they are needed.

Mast cells seem to have other roles as well. Because they gather together around wounds, mast cells may play a part in wound healing. For example, the typical itching you feel around a healing scab may be caused by histamine released by mast cells. Researchers also think mast cells may have a role in the growth of blood vessels (angiogenesis). No one with too few or no mast cells has been found, which indicates to some scientists that we may not be able to survive with too few mast cells.

Mast cells express a cell surface receptor termed c-kit (CD117), which is the receptor for scf (stem cell factor). In laboratory studies, scf appears to be important for the proliferation of mast cells, and inhibiting the tyrosine kinase receptor with imatinib (see below) may reduce the symptoms of mastocytosis.

History

Scientists first described urticaria pigmentosa in 1869. Systemic mastocytosis was first reported by scientists in 1936.

Symptoms

Chemicals released by mast cells cause changes in the immune system leading to typical allergy symptoms such as:

  • itching
  • abdominal cramping
  • and even anaphylaxis (shock from allergic or immune causes)

When too many mast cells exist in a person's body, the additional chemicals can cause:

  • Skin lesions
  • Abdominal discomfort
  • Diarrhea
  • Stomach ulcers
  • Episodes of very low blood pressure (including shock) and faintness
  • bone or muscle pain
  • Nausea and vomiting

Diagnosis

Doctors can diagnose urticaria pigmentosa (cutaneous mastocytosis, see below) by seeing the characteristic lesions which are dark-brown and fixed. A small skin sample (biopsy) may help confirm the diagnosis.

By taking a biopsy from a different organ, such as the bone marrow, the doctor can diagnose systemic mastocytosis. Using special techniques on a bone marrow sample, the doctor looks for an increase in mast cells. Another sign of this disorder is high levels of certain mast-cell chemicals and proteins in a person's blood and sometimes in the urine.

Read more at Wikipedia.org


[List your site here Free!]


Solitary mastocytoma successfully treated with a moderate potency topical steroid
From Journal of Drugs in Dermatology, 5/1/04 by Iqbal A. Bukhari

Abstract

We report a case of solitary mastocytoma in a child which was successfully treated with a topical steroid of moderate potency. The patient was an 18-month-old girl who presented with localized oval shape yellowish to hyperpigmented lesion on the medial aspect of her right forearm noticed accidentally by the parents since the age of 6 months. The lesion was observed to get urticated mainly after bathing, toweling, and scratching of the area, associated with reddening and itching confined to the lesion (Figure 1). No other area of the body was affected with any similar lesion.

Examination of the skin revealed a yellow-tan oval shape patch 1 X 3 cm in diameter which was firm to the touch with intact overlying skin. The lesion became swollen and itchy when it was rubbed vigorously (positive Darier's sign). Systemic examination was unremarkable. The patient investigations including complete blood count, routine biochemical data, plasma histamine level, and urinalysis were within normal levels. Skin biopsy was cancelled because the parents refused, so our clinical diagnosis was solitary mastocytoma even though it was not confirmed histologically. We started the patient on a moderate potency corticosteroid (betamethasone valerate 0.1% cream) twice a day for six weeks after which the lesion became softer with a weak Darier's sign. This treatment was continued for another four months which led to resolution of the lesion with residual hyperpigmentation, negative Darier's sign, and no signs of atrophy (Figure 2). Follow up of the patient for another 8 weeks without treatment did not reveal any recurrence of the lesion.

**********

[FIGURE 1 OMITTED]

[FIGURE 2 OMITTED]

Solitary mastocytoma is a condition that occurs in infants characterized by localized mast cell hyperplasia and release of their mediators. It is one of the common manifestations of pediatric mastocytosis followed by urticaria pigmentosa (1). It usually appears in infants before their sixth month as a single rounded hyperpigmented macular, tuberous, or nodular lesion which grows gradually over a period of several months up to 4 cm in diameter, at which point the lesion stabilizes and tends to regress for as long as up to 7 years (2-5). Pruritis is the primary presenting symptom in children with mastocytosis, which could be intermittent or continuous, and associated with large areas of excoriation. Additional systemic symptoms such as vomiting, colicky pain, diarrhea, headache, and bullae are to be expected in patients with urticaria pigmentosa or diffuse cutaneous mastocytosis. The diagnosis is based on the clinical appearance of the lesions and elicitation of Darier's sign, and confirmed by biopsy which shows mast cell hyperplasia (6).

Spontaneous total regression is the natural course in 25% of mastocytoma cases; in another 25% the regression is partial, which indicates that treatment is not often recommended (5,6). The rest are usually treated symptomatically by H1 and H2 blockers and mast cell stabilizing agents such as sodium cromoglycate. Strong topical steroids and intralesional triamcinolone injections are used over limited areas only. They exert their effect through inhibition of histamine release and other mediators by mast cells and reducing mast cell number by inhibiting polymorphonuclear leukocyte chemotaxis. Though these effects are more pronounced with the use of more potent topical steroids, there is risk of developing atrophy if used for many months continuously (7-10). In our case we used a moderately potent topical steroid (betamethasone valerate) twice a day for a total of 22 weeks without occlusion which resulted in resolution of the lesion with hyperpigmentation but with no signs of atrophy or other side effects related to topical steroids. In conclusion, this case demonstrated the effect of using a less potent steroid in solitary mastocytoma to speed its resolution without worrying about the side effects caused by potent steroids.

Referencess:

1. Kacker A, et al. Solitary mastocytoma in an infant-case report with review of literature. Int J Pediatr Otorhinolaryngol 2000; 52:93-95.

2. Chargin L. Sachs P. Urtecaria pigmentosa appearing as solitary nodular lesion. Arch Dermatol Syphil 1954; 69:345-355.

3. Dermis J. The mastocytosis syndrome: clinical and biological studies. Ann Intern Med 1963; 59: 194-206.

4. Longley J, Duffy T, Khon S. The mast cell and mast cell disease. J Am Acad Dermatol 1995; 32:545-561.

5. Torrelo A, et al. Diagnostico, tratamiento y classification de la mastocitosis pediatrica. Estodio de 172 casos. Actas Dermosifilioger 1998; 89:461-476.

6. Loubeyres S, et al. Classification and management of mastocytosis in the child. Ann Dermatol Venereol 1999; 126: 20-25.

7. Soter NA. The skin in mastocytosis. J Investi Dermatol 1991; 96(suppl.):32S-39S.

8. Guzzo C, et al. Urtecaria pigmentosa. Systemic evaluation and successful treatment with topical steroid. Arch Dermatol 1991; 127:191-196.

9. Lavker R, Schecher N. Cutaneus mast cell depletion results from topical corticosteroid usage. J Immunol 1985; 35:2368-2373.

10. Mateo J. Mastocytoma: topical corticosteroid treatment. J Eur Acad Dermatol Venereol 2001; 15:492-493.

IQBAL A BUKHARI MD

ASSISTANT PROFESSOR AND CONSULTANT DERMATOLOGIST DERMATOLOGY DEPARTMENT, COLLEGE OF MEDICINE, KING FAISAL UNIVERSITY HOSPITAL ALKHOBAR, SAUDI ARABIA

ADDRESS FOR CORRESPONDENCE:

Iqbal A Bukhari MD

Assistant Professor

Dermatology Dept., College of Medicine

King Faisal University Hospital

PO Box 40189

Alkhobar 31952, Saudi Arabia

E-mail: consultant@dermatologyclinics.net

COPYRIGHT 2004 Journal of Drugs in Dermatology
COPYRIGHT 2004 Gale Group

Return to Systemic mastocytosis
Home Contact Resources Exchange Links ebay